InKine Pharmaceutical Co. Inc. said its pre-colonoscopy bowel-cleansing drug, INKP-102, met or exceeded endpoints in a Phase III trial compared to the company's marketed purgative product, Visicol. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for Dec. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 27, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Probing bidirectional cancer-autoimmune link can yield new targets
BioWorld Science
Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.